AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05550402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
Study NCT04921254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSG005 or placebo
Description: SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level.
Study NCT04921254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSG005 or placebo
Description: SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level.
Study NCT04714073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321
Study NCT04714073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study NCT04586348 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Iodine Supplement
Description: Multivitamin and mineral supplement with reduced iodine
Study NCT04586348 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Iodine Supplement
Description: Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
Study NCT06410261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program
Description: * The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance.
Study NCT05083013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription polymerase chain reaction (RT-PCR)
Description: For SARS Corona Virus 2 (COV2) confirmation
Study NCT05083013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated haemoglobin (HbA1C)
Description: Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
Study NCT05083013 — intervention group
Intervention type: RADIATION
Intervention: High Resolution Computed Tomography (HRCT)
Description: with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
Study NCT05083013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Laboratory investigations
Description: * Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)
Study NCT05083013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Random Blood Sugar (RBS)
Description: Blood Sugar will be measured before each meal and before bed time during hospitalization.
Study NCT05158335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109 (Part A)
Description: Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
Study NCT05158335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109 (Part B)
Description: Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
Study NCT05158335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose or repeated SC doses of placebo.
Study NCT06010641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-down position
Description: -20° Trendelenburg as an adjunct to guideline-based treatment,
Study NCT06010641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: head-down position
Description: -20° Trendelenburg as an adjunct to guideline-based treatment,
Study NCT04137588 — intervention group
Intervention type: DRUG
Intervention: Antiangiogenesis Agents
Description: antiangiogenesis agents plus chemotherapy as first line treatment
Study NCT04137588 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor plus chemotherapy as first line treatment
Study NCT06319469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet
Description: The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
Study NCT06319469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin 8 mg capsule
Description: The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
Study NCT05201430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
Study NCT05201430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOX
Description: oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
Study NCT05717374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal block using dexamethasone
Description: patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
Study NCT05717374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal block using methylprednisolone
Description: patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
Study NCT03681392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Pyke's Supplement for Stream (S4S)
Description: Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
Study NCT06359067 — intervention group
Intervention type: OTHER
Intervention: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Description: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Study NCT06359067 — intervention group
Intervention type: OTHER
Intervention: Not treated by bispecific antibodies in usual care
Description: Not treated by bispecific antibodies in usual care
Study NCT06166849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Fluoride Application
Description: The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
Study NCT03764865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: day 3 uterine transfer
Description: uterine transfer of embryo on day 3 after fertilization (cleavage stage)
Study NCT03764865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: day 5 uterine transfer
Description: uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
Study NCT06135220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.
Description: The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
Study NCT05292040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally.
Study NCT05911776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal packing Dexmedetomidine
Description: patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
Study NCT05911776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexmedetomidine
Description: patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
Study NCT05495841 — intervention group
Intervention type: DEVICE
Intervention: Pre-oxygenation
Description: Process of administrating oxygen prior to intubation
Study NCT05499455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional Sleep Belt
Description: Rematee Positional Sleep Belt
Study NCT05499455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control Device
Study NCT06584331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 dose of Beetroot juice intake
Description: The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
Study NCT06584331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 doses of Beetroot juice intake
Description: This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
Study NCT06584331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
Study NCT05692934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
Study NCT05692934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
Study NCT05692934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
Study NCT05692934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
Study NCT05553340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education for caregivers
Description: The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
Study NCT06331416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
Study NCT04542785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
Study NCT04542785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
Study NCT05496387 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sciatic nerve neuromobilization techniques
Description: Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
Study NCT05496387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic nerve neuromobilization techniques
Description: Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
Study NCT05412238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-and macro-nutrients fortified sachets
Description: Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
Study NCT04513288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental treatment L-citrulline (Protéocit®)
Description: Enteral administration of citrulline for 5 days.
Study NCT04513288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Enteral administration of iso-nitrogenous placebo for 5 days.
Study NCT05842044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
Study NCT05842044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
Study NCT04761679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applying the Mepilex foam
Description: Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
Study NCT05037591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
Study NCT05497102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Description: Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
Study NCT06411886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen challenge
Description: Inhaled allergen
Study NCT06411886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Saline challenge
Description: Inhaled saline
Study NCT05480215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala Device
Description: transcutaneous afferent patterned stimulation (TAPS)
Study NCT05108454 — intervention group
Intervention type: DRUG
Intervention: Multiple micronutrient supplementation
Description: Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
Study NCT05550870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw fenugreek seed powder
Description: It will be given to group 1
Study NCT05550870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roasted fenugreek seed powder
Description: It will be given to group 2
Study NCT05311449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
Study NCT05311449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo acupressure
Description: In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study NCT05037591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study NCT05842044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
Study NCT05842044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization.
Study NCT05577312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL-101
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
Study NCT05410171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early warning platform
Description: High risk inpatients will be evaluated by early warning platform